Item 8.01. Other Events.

On September 19, 2020, the Company issued a press release titled "Trodelvy(TM) Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer". The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

On September 19, 2020, the Company issued a press release titled "Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy(TM) in Metastatic Urothelial Cancer". The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.2 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibits are being filed herewith:



Exhibit            Exhibit
No.

  99.1               Press Release of Immunomedics, Inc., dated September 19,
                   2020

  99.2               Press Release of Immunomedics, Inc., dated September 19,
                   2020

104                The cover page from this Current Report on Form 8-K, formatted
                   in Inline XBRL

© Edgar Online, source Glimpses